TSX futures subdued as gold rally takes a breather
LONDON - Haleon plc (LSE/NYSE:HLN) announced Wednesday it will implement Salesforce (NYSE:CRM) technology to improve its engagement with pharmacies and healthcare professionals globally. Salesforce, with its impressive $228 billion market capitalization and industry-leading 77.65% gross profit margins, has established itself as a dominant force in enterprise software solutions.
The consumer health company, known for brands like Sensodyne and Centrum, will equip its 4,500-member sales force with Salesforce Life Sciences Cloud for Customer Engagement, Data Cloud, and Agentforce. According to the company’s press release statement, the AI-powered solution aims to provide sales representatives with data-driven insights on consumer demographics, shopping trends, and point-of-sale marketing. InvestingPro analysis shows Salesforce maintains a perfect Piotroski Score of 9, indicating exceptional financial strength and operational efficiency.
Haleon will also serve as a design partner for Salesforce Life Sciences Cloud for Customer Engagement, contributing to the development of solutions specific to the consumer health industry.
"This selection of Life Sciences Cloud and Agentforce will enable pharmacists and healthcare professionals to more efficiently deliver better everyday health to millions of people all around the world," said Claire Dickson, Chief Digital and Technology Officer at Haleon. According to InvestingPro, which offers comprehensive analysis of 1,400+ stocks through its Pro Research Reports, Salesforce is currently trading near its 52-week low, presenting a potentially attractive entry point for investors interested in the software giant’s growth story.
Frank Defesche, General Manager of Life Sciences at Salesforce, stated the partnership will "reimagine how the consumer health industry engages with pharmacies and HCPs through real-time insights and trusted AI."
The implementation is expected to reduce administrative tasks for sales representatives, allowing them to focus on creating bespoke activation plans for customers.
The Order Management feature is expected to be available as part of Life Sciences Cloud for Customer Engagement starting October 2026, according to the announcement. Salesforce’s strong financial health score of 2.99 from InvestingPro suggests the company is well-positioned to deliver on its development commitments and maintain its market leadership.
In other recent news, Salesforce has informed its customers that it will not pay a ransom to the hacker group ShinyHunters, which threatened to release client data stolen during a security incident earlier this year. Truist Securities has reiterated its Buy rating on Salesforce stock, maintaining a $400 price target, while noting potential catalysts that could boost investor sentiment despite uncertainty around AI and Agentforce adoption. JMP Securities also reaffirmed a Market Outperform rating with a $430 price target, following a presentation by Hubbl Technologies, a company within the Salesforce ecosystem.
Additionally, BNP Paribas Exane has maintained an Outperform rating with a $305 price target, highlighting Salesforce’s addition of 2,000 paying Agentforce customers, doubling the previous quarter’s increase. Meanwhile, Youxin Technology has announced the acquisition of a 51% stake in Celnet Technology, China’s largest Salesforce partner, for approximately RMB 5.24 million (US$736,461) in cash, along with additional equity and cash incentives. These developments come amid Salesforce’s reiteration of its fiscal year guidance despite a 5% drop in stock value. Investors and analysts continue to monitor Salesforce’s strategic movements and partnerships as the company navigates a challenging demand environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.